FDA OKs Varisolve varicose vein therapy trial:
This article was originally published in Clinica
Executive Summary
BTG's subsidiary Provensis has gained approval from the US FDA to begin a pilot clinical study of its noninvasive procedure for treating varicose veins. The technique, called Varisolve, involves injecting a microfoam version of a standard sclerosing liquid into the vein under ultrasound guidance. Efficacy data from an ongoing trial in Europe are expected to become available by the end of the year, at which time BTG plans to begin discussions with potential sales and marketing partners. London, UK-based BTG forecasts 2006 and 2005 launch dates for Varisolve in the US and in Europe, respectively.